Role of Immunotherapies Emerging in Gastric/GEJ Cancers – OncLive
OncLive |
Role of Immunotherapies Emerging in Gastric/GEJ Cancers
OncLive While immune checkpoint inhibitors, specifically PD-1 inhibitors, are the furthest along in development, there are studies looking at combination immunotherapy regimens. Nivolumab has been looked at and is approved in Asia as a monotherapy for gastric … |
